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Introduction
Over 80% of women with advanced breast cancer ulti-
mately develop bone metastases that result in significant
morbidity and mortality. Breast cancer metastases in bone
can cause intractable pain, bone fracture, spinal cord
compression and hypercalcaemia [1–3]. From the moment
breast cancer cells arrive in the bone microenvironment,
however, they stimulate bone resorption with subsequent
selective increase in the attraction and growth of new
cancer cells to bone [4]. Therefore, any treatment aimed at
palliation or perhaps even prevention of bone metastases
should focus on disrupting this attraction and growth,
which are involved in the initiation and amplification of the
metastatic process.
Bisphosphonates are widely used for the treatment of
bone metastases, and an increasing body of evidence
suggests that these compounds provide benefit to breast
cancer patients with secondary cancers in bone [5]. Bis-
phosphonates are analogues of endogenous pyrophos-
phates in which a carbon atom replaces the central atom
of oxygen. In vivo, bisphosphonates bind strongly to
hydroxyapatite on the bone surface and are preferentially
delivered to sites of increased bone formation or resorp-
tion. They are potent inhibitors of osteoclast-mediated
bone resorption [6] and are effective in lowering serum
calcium concentrations in patients with hypercalcaemia of
malignancy [7,8]. Treatment with bisphosphonates has
also been shown to reduce skeletal morbidity significantly
and to improve quality of life in breast cancer patients with
bone metastases [7].
The mechanisms by which bisphosphonates inhibit osteo-
clast-mediated bone resorption appear to involve an inhibi-
tion of formation of osteoclasts from immature precursor
cells [6,9,10] or direct inhibition of resorption via induction
of apoptosis in mature osteoclasts [9,11,12]. Furthermore,
as outlined elsewhere, bisphosphonate treatment has been
shown to inhibit the progression and development of bone
metastases in a mouse model of breast cancer [13,14].
Such a beneficial effect of bisphosphonates on tumour
burden in bone may result from a direct antitumour effect
on breast cancer cells. Evidence is now emerging that this
is indeed the case and that treatment of cultured human
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breast cancer cells treated with bisphosphonates induces
inhibitory effects on adhesion, invasion and cell survival.
Effects of bisphosphonates on cell adhesion
to and invasion of bone
It is well accepted that adhesion of cancer cells to bone
matrix is a vital step in the bone metastasis process, and it
has been suggested that exposure of bone to bisphospho-
nates could alter properties of the bone matrix that are
required for adhesion of breast cancer cells. In this regard,
previous studies [6,9,15] have indicated that exposure of
calcified matrix of bone to bisphosphonates in vitro alters
the properties of the bone matrix that are required for
attachment of the osteoclast.
Initially, the ability of human breast cancer cells to adhere
to bone matrices that had been pretreated with bisphos-
phonates was investigated by van der Pluijm et al. [16]. In
those experiments adhesion of MDA-MB-231 human
breast cancer cells to bovine cortical bone slices and sec-
tions of developing trabecular bone from neonatal mouse
tail were assessed. Those studies showed that pretreat-
ment of bone matrices with certain bisphosphonates at
concentrations of 1–100 µmol/l not only prevented adhe-
sion of breast cancer cells to bone matrix, but also inhib-
ited cell spreading. However, of the bisphosphonates
tested only pretreatment of matrices with nitrogen-contain-
ing bisphosphonates (pamidronate, olpandronate, alen-
dronate and ibandronate) led to these inhibitory effects.
Ibandronate was found to be the most potent compound.
Pretreatment with clodronate or etidronate did not affect
adhesion to bone matrix or cell spreading, and the order of
potency of the six bisphosphonates corresponded to their
ranking in bone resorption assays [6,9]. No effects on cell
viability were observed over the 3 h period during which
the cells were allowed to adhere to bone matrices.
Subsequently, Boissier et al. [17] evaluated the effect of
direct treatment of breast cancer cells with bisphospho-
nates on their ability to adhere to unmineralized and miner-
alized bone extracellular matrices. Using mineralized bovine
cortical bone slices and unmineralized extracellular matri-
ces produced by cultured osteoblastic cells, those investi-
gators found that pretreatment of MCF-7 and
MDA-MB-231 breast cancer cells for 24 h with bisphos-
phonates inhibited cell adhesion. Similar effects were
found with cultured prostatic carcinoma cells. Of the bis-
phosphonates used, only ibandronate, NE-10244 (antire-
sorptive active pyridinium analogue of risedronate) and
pamidronate inhibited cell adhesion at low concentrations,
with half-maximal inhibitions at 5 pmol/l, 0.1 nmol/l and
10 nmol/l, respectively. Clodronate achieved the same
inhibitory effects at a high concentration, with half-maximal
inhibition at 10 µmol/l. At concentrations that inhibited cell
adhesion after 24 h of treatment, no effects of bisphospho-
nates on cell viability or integrin expression were detected.
The mechanism by which the various bisphosphonates
inhibit cell adhesion when coated onto mineralized or
unmineralized matrix does not relate to their direct inhibitory
action when incubated with cells in vitro. Thus, the ana-
logue NE-58051 (inactive pyridylpropylidene analogue of
risedronate, which lacks a methyl group in the R2 chain of
the molecule; Fig. 1) was effective in preventing cell adhe-
sion when cortical bone slices were coated with this com-
pound [17]. However, pretreatment of cultured breast
cancer cells in vitro with NE-58051, before seeding onto
uncoated bone slices, did not affect adhesion.
The taxoids taxol and taxotere are effective antitumour
compounds that are currently used routinely in the treat-
ment of metastatic breast carcinoma. Magnetto et al. [18]
determined whether there could be additive or synergistic
effects of bisphosphonates in combination with taxoids on
adhesion of breast cancer cells to bone. Using cortical
bone slices, it was shown that exposure of MDA-MB-231
cells to taxoids for 1 h inhibited adhesion to mineralized
bone matrices in a dose-dependent manner, with half-
maximal inhibition seen with approximately 80 nmol/l for
both taxoids. However, the concentrations of taxoids used
to inhibit cell invasion (up to 500 nmol/l) were 25-fold
higher than the concentrations required to induce apopto-
sis. In combination experiments the inhibitory effect of
ibandronate on cell adhesion was additive to that of
taxoids. Studies done using matrigel invasion assays
revealed that exposure of breast cancer cells to iban-
dronate for 23 h followed by 1 h exposure to taxoids
increased inhibitory effects on cell invasion by 70–78% as
compared with taxoids alone.
Because breast cancer cell invasion requires both cell
migration and digestion of the basement membrane by
matrix metalloproteinases (MMPs), bisphosphonates
could affect one or the other of these mechanisms.
Because ibandronate treatment did not inhibit cell migra-
tion in the study of Magnetto et al. [18], it is possible that
the bisphosphonate mediates effects on cell invasion by
decreasing production of MMPs or by inhibiting their activ-
ity. Using similar methods, those investigators determined
the order of potency of four bisphosphonates in the inva-
Figure 1
Structure of bisphosphonates.
O
– O
O O
O O
P P C
R2
R1
–
– –Breast Cancer Research    Vol 4 No 1 Senaratne and Colston
sion assay [19]. The order of potency was found to be as
follows: zoledronic acid > ibandronate > NE-10244
(active analogue) > clodronate. The half-maximal inhibition
values were found to be <1 pmol/l, 1 pmol/l, 0.5 nmol/l
and 50 µmol/l, respectively.
NE-58051 had no inhibitory effects on cell invasion [19],
which is in accord with its ineffectiveness in preventing cell
adhesion, as outlined above. This indicates that the direct
inhibitory action of bisphosphonates on breast cancer cells
involves the R2 group of the molecule (Fig. 1). On the other
hand, NE-10790 (a phosphonocarboxylate analogue of
risedronate, in which one of the phosphonate groups is
substituted by a carboxyl group) had inhibitory effects on
cell invasion to an extent similar to that observed with
NE-10244, even though NE-10790 has little effect on
antiresorptive activity as compared with NE-10244 on
bone. This suggests that the pharmacological mechanism
of action of bisphosphonates on tumour cell invasion is
distinct from the mechanism of action on bone.
The results from that study [19] also lend support to the
suggestion that the inhibitory effects of bisphosphonates
on cell invasion are related to the inhibition of the proteo-
lytic activity of MMPs rather than to modulation of their
expression. At high concentrations (~100 µmol/l), bisphos-
phonate treatment inhibited the activity of MMP-2, -9 and 
-12. Excess of zinc completely reversed bisphosphonate-
induced inhibition of cell invasion. In addition, NE-10790
did not inhibit MMP activity. Those findings suggest that
the phosphonate groups of bisphosphonates are respon-
sible for the chelation of zinc and the subsequent inhibi-
tion of MMP activity. However, although treatment with
NE-10790 did not decrease MMP activity, it inhibited
breast cancer cell invasion to an extent similar to that
observed with NE-10244; this suggests that inhibition of
MMP activity is not the sole mechanism by which bisphos-
phonates inhibit invasion.
Effects of bisphosphonates on breast cancer
cell growth and apoptosis
Previous studies have shown that bisphosphonates
reduce metastatic tumour burden in bone with increased
apoptosis in osteoclasts [20]. In addition, a number of in
vitro studies have indicated that bisphosphonate treat-
ment of myeloma cells leads to growth inhibition and
induction of apoptosis [21]. Clinical findings have sug-
gested that clodronate treatment may reduce incidence of
bone metastases, although these results are not yet con-
clusive [22]. Taken together, these results indicate that
bisphosphonates may exert direct growth inhibitory effects
on breast cancer cells, leading to reduced metastatic
tumour burden in bone.
This suggestion was confirmed by our group with the
demonstration that treatment of cultured breast cancer
cells with bisphosphonates leads to growth inhibition and
induction of apoptosis [23]. In those initial studies, a non-
reversible inhibition of cell growth and viability of three
human breast cancer cell lines was seen, together with
morphological and biochemical changes consistent with
apoptosis. Four structurally different bisphosphonates
(zoldedronic acid, pamidronate, clodronate and EB-1053)
induced apoptosis in a time- and dose-dependent manner.
Zoledronic acid was found to be the most potent bisphos-
phonate, with half-maximal inhibition values in MDA-MB-
231 cells of 15 µmol/l; the corresponding values for
pamidronate, EB-1053 and clodronate were 40, 1000
and 700 µmol/l, respectively. Furthermore, the order of
potency of the bisphosphonates was similar in all three
cell lines tested. This finding is in contrast to that of Busch
et al. [24], who reported that clodronate is able to reduce
survival of MDA-MB-435S but not that of MCF-7 cells.
Our findings indicate that the order of bisphosphonate
potency on bone resorption is not equivalent to that for
inhibiting cell viability in breast cancer cells [23]; it is cell-
type-specific. Zoledronic acid has been reported to be
100 times more potent than pamidronate in reducing bone
resorption [25], and our study suggests it is approximately
threefold more potent than pamidronate in reducing cell
viability in breast cancer cells. EB-1053, which is 100
times more potent than pamidronate in inhibiting bone
resorption in rats [25], was substantially less effective on
breast cancer cells.
We found evidence for fragmentation of chromosomal
DNA, a key feature of apoptosis, in MCF-7, MDA-MB-231
and Hs578T breast cancer cells after 2–3 days of treat-
ment with bisphosphonates (Fig. 2) [23]. Induction of
apoptosis in MDA-MB-231 cells by pamidronate was
accompanied by decreased expression of the antiapop-
totic protein bcl-2 as well as cleavage of poly (ADP-
ribose) polymerase, thus implicating the activation of a
caspase-dependent pathway. This was later confirmed by
Fromigue et al. [26], who showed that inhibition of MCF-7
cell proliferation by four bisphosphonates (zoledronic acid,
ibandronate, pamidronate and clodronate) could be abro-
gated by cotreatment with z-VAD-fmk, a broad-spectrum
caspase inhibitor. We similarly found that z-VAD-fmk
attenuates loss of MDA-MB-231 breast cancer cell viabil-
ity in response to pamidronate (Fig. 3) and identified
caspase-3 as one of the cell death proteases that are acti-
vated by zoledronic acid treatment in MDA-MB-231 cells
[27]. Furthermore, Hiraga et al. [28] demonstrated that a
selective caspase-3 inhibitor is capable of blocking iban-
dronate-induced DNA fragmentation in these breast
cancer cells.
A recent report by Jagdev et al. [29] presents evidence for
synergistic effects of zoledronic acid and paclitaxel on
induction of apoptosis in MCF-7 and MDA-MB-231 breastcancer cells. Those investigators found a fourfold to five-
fold increase in induction of apoptosis in MCF-7 cells
when zoledronic acid was used in combination with pacli-
taxel. This finding is in accord with previous findings of
additive effects of bisphosphonates and taxoids on inhibi-
Available online http://breast-cancer-research.com/content/4/1/018
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Figure 2
(a) Hs 578T, MDA-MB-231 and MCF-7 breast cancer cells were
treated for 2 days with 100 µmol/l zoledronic acid. The percentage of
fragmented chromosomal DNA was measured in cells treated with
zoledronic acid and compared with that of control (vehicle-treated)
cells as previously described [23]. *P < 0.0005 versus control. 
(b) Apoptosis was examined by electrophoretic analysis of
internucleosomal DNA fragmentation following treatment of MDA-MB-
231 cells with 10 and 100 µmol/l pamidronate for 3 days.
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Figure 3
(a) Attenuation by broad-spectrum caspase inhibitor z-VAD-fmk
(zVAD) of the effects of pamidronate (APD) on cell viability in MDA-
MB-231 cells. Cells were plated in 96-well plates (1 × 103 cells/well)
and treated with 50 µmol/l zVAD 1 h before addition of 30 µmol/l APD
for 3 days. On days 1, 2 and 3, cell viability was quantitated using MTS
dye reduction assay. Results are shown as mean ± SD. **P < 0.0001
versus APD + zVAD treatment. (b) Effects of zVAD on APD-induced
DNA fragmentation in MDA-MB-231. Cells were plated in 6-well plates
at a density of 1 × 106/well and treated with 50 µmol/l of zVAD for 1 h
before addition of 30 µmol/l APD for 4 days without renewal of
medium. Cotreatment with zVAD significantly reduced APD-induced
DNA fragmentation. *P < 0.0005 versus APD treatment alone.
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(b)tion of breast cancer cell invasion and adhesion. In addi-
tion, Hiraga et al. [28] reported that bisphosphonates
directly induce apoptosis in breast cancer cells that
metastasize to bone. Ibandronate (4 µg/mouse per day
subcutaneously) was administered after bone metastases
had been established by intracardiac inoculation of MDA-
MB-231 cells. Inhibition of progression of established
osteolytic bone metastases was demonstrated by radio-
logical analysis. Ibandronate significantly decreased
tumour burden and increased MDA-MB-231 cell apopto-
sis in bone metastases. Ibandronate treatment was not
able to induce apoptosis in tumours developed by inocula-
tion of MDA-MB-231 cells in the orthotopic mammary fat
pads, however, indicating that effects of ibandronate on
breast cancer cell apoptosis are restricted to bone in
which ibandronate selectively deposits.
The mechanisms by which bisphosphonates promote
breast cancer cell apoptosis remain to be established. In
osteoclasts and myeloma cells it has been suggested that
nitrogen-containing bisphosphonates induce apoptosis by
inhibiting enzymes in the mevalonate pathway, preventing
the generation of isoprenoid moieties and thereby impairing
the isoprenylation (farnesylation and geranylgeranylation) of
small GTP proteins such as Ras, Rho and Rac [11,30,31].
Jagdev et al. [29] recently presented evidence that loss of
MCF-7 cell viability induced by zoledronic acid could be
prevented by coincubation with geranylgeraniol, suggest-
ing a role for impaired protein geranylgeranylation in the
effects of the bisphosphonate. The identity of the protein
that is affected by zoledronic acid treatment remains to be
determined, however. Our own studies have shown that
treatment of both MCF-7 and MDA-MB-231 cells with
zoledronic acid leads to impaired membrane localization of
Ras that is consistent with impaired farnesylation [27].
Further studies are required to determine the signal trans-
duction pathways that are modulated by the alterations in
protein isoprenylation induced by bisphosphonates.
Conclusion
Laboratory studies increasingly suggest that bisphospho-
nates can induce important antitumour effects in breast
cancer cells in vitro by promoting apoptosis, and inhibiting
cell adhesion and invasive potential. It is therefore possi-
ble that the beneficial effects reported in patients receiv-
ing treatment with bisphosphonates may involve direct
effects on tumour cells in bone as well as inhibition of
osteoclast-mediated bone resorption. It has been noted,
however, that the in vitro concentrations of bisphospho-
nates required to induce breast cancer cell apoptosis are
higher than those required for osteoclast apoptosis. At the
present time the concentrations of bisphosphonates to
which tumour cells in bone are exposed are unclear.
Bisphosphonates bind to hydroxyapatite by virtue of their
carbon-substituted pyrophosphate structure, and this
accounts for their selective action on the skeleton. The
local concentrations of bisphosphonate released from the
hydroxyapatite surface into the resorption space are prob-
ably considerably higher than the circulating concentra-
tion, and have been suggested to approach 800 µmol/l
[32]. If this is the case then cancer cells may be exposed
to concentrations that are sufficient to induce apoptosis.
In summary, the newly recognized direct actions of bispho-
sphonates on breast cancer cell adhesion, invasion and
cell viability indicate that these agents may have a wider
role to play in prophylactic treatment of patients suffering
from cancers with a propensity to metastasize to bone.
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